Finite Basis Theorem for Filter-distributive Protoalgebraic Deductive Systems and Strict Universal Horn Classes

We show that a finitely generated protoalgebraic strict universal Horn class that is filter-distributive is finitely based. Equivalently, every protoalgebraic and filter-distributive multidimensional deductive system determined by a finite set of finite matrices can be presented by finitely many axioms and rules.     

Contemporary ‘people from hideouts’ and the problem of the lack of social involvement

Studies in East European Thought - The aim of this paper is to present Tischner’s concept of ‘people from hideouts’ in the context of contemporary problems of lack of social...     

No Matrix Term-Equivalent to Wroński's 3-element Matrix is Finitely Based

Motivated by a question of W. Rautenberg, we prove that any matrix that is term-equivalent to the well-known nonfinitely based matrix of A. Wroski is itself also nonfinitely based.     

Sergei Hessen, Neo-Kantian Dedicated to Professor Andrzej Walicki

This paper commemorates thepresentation of the honorary doctorate, in May2001 by the University of ód, toProfessor Andrzej Walicki. On this occasion,the Honorary Graduate delivered a lecturedevoted to his first philosophy teacher –Sergej Iosifovich Hessen, a prominent RussianNeo-Kantian philosopher and a liberal inmatters social and political. I try to analyzethe main features of Hessen's philosophicalneo-Kantianism, in particular the inevitabilityof a choice between the absolute and therelative both in epistemology and in ethics inthe context of contemporary philosophy.     

Placebo in the investigation of psychotropic drugs,especially antidepressants

The paper presents major ethical, legal and methodological problems related to the use of placebo in mental disorders, especially in depression. It is pointed out that although authoritative groups of experts and numerous publications in the field of psychopharmacology indicate advisability of the double blind design with placebo in clinical trials of antidepressants, in recent years there have been more and more voices questioning legitimacy of this method. Objections of an ethical nature are raised, and reliability of this approach is put into doubt from the methodological viewpoint. These issues are discussed in more detail in the paper. Available alternative solutions should be implemented in psychotropic drug studies. The author shares these objections and doubts of an ethical nature, and believes that the placebo procedure is not a necessity in clinical trials of antidepressants. An earlier version of this paper was presented at an international conference, “Placebo: Its Action and Place in Health Research Today,” held in Warsaw, Poland on 12–13 April, 2003.     

Clinical trials: active control vs placebo — What is ethical?

The quest for effective medicines is very old. In modern times two important tools have been developed to evaluate efficacy of drugs: superiority and non-inferiority types of clinical trials. The former tests the null hypothesis of μ (the difference between a tested drug and comparator) ≤ 0 against μ > 0; the latter tests the null hypothesis of μ ≤ - Δ against, μ > - Δ, where Δ is the clinical difference from the comparator. In a superiority trial, a new drug is tested against a placebo; in a non-inferiority trial, a new drug is tested against active treatment. In this paper, arguments are presented to show that a superiority trial against a placebo is scientifically sound but ethically unacceptable, whereas a non-inferiority trial against active treatment is ethically sound but scientifically not reliable. Switching from a superiority type of trial with placebo to a non-inferiority trial with an active-control — following the latest revision of Declaration of Helsinki — is in practice switching from the violation of the uncertainty principle to uncertainty of results. Given human and financial resources, it appears an academic question as to which is more unethical: to violate patients’ rights or to produce results without scientific value. All presented considerations lead to the conclusion that the use of a superiority trial of design with an active control instead of placebo will satisfy scientific needs, expectation of patients, and the ancient quest for effective medicines. In the era of Good (Clinical, Laboratory, Manufacture) Practice, the attention of those performing clinical trials is focused on the procedure, not always on its essence. However even the excellent performance of a trial which is not worth doing is fruitless. An earlier version of this paper was presented at an international conference, “Placebo: Its Action and Place in Health Research Today,” held in Warsaw, Poland on 12–13 April, 2003.     

Löb's Theorem in a Set Theoretical Setting

We present a semantic proof of Löb's theorem for theories T containing ZF. Without using the diagonalization lemma, we construct a sentence AUT _T, which says intuitively that the predicate autological with respect to T (i.e. applying to itself in every model of T) is itself autological with respect to T. In effect, the sentence AUT _T states I follow semantically from T. Then we show that this sentence indeed follows from T and therefore is true.